EUVIMEDEUVIMED entdecken
Crossref

Postmarketing Safety Signals and Medication‐Use Risks of GLP ‐1‐Based Therapies in Diabetes and Obesity: A Multi‐Source Pharmacovigilance and Regulatory Evidence‐Mapping Study

Long Ren, Yuan Zhang, Fang Fang, Yabin Ma iD

Diabetes, Obesity and Metabolism · 2026-12 · 28 (12) · 11076-11085

DOI: 10.1111/dom.71303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 03.09.2026. Verfasst von Long Ren und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Pharmacovigilance, Obesity, Product Surveillance, Postmarketing, Hypoglycemic Agents. Die Arbeit nennt 51 Literaturangaben. Gefördert von: Shanghai Municipal Science and Technology Commission Project, Pudong New District Health Technology Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To characterise postmarketing safety signals and medication‐use risks associated with GLP‐1 receptor agonists and the GIP/GLP‐1 co‐agonist tirzepatide in diabetes and obesity care using an integrated pharmacovigilance, utilisation‐context, regulatory, and external‐consistency framework. Materials and Methods FDA Adverse Event Reporting System (FAERS) data from 2021Q1 through 2026Q1 were processed using deleted‐case exclusion, latest‐case‐version retention, and case‐product deduplication with analysis at the GLP‐1 primary‐suspect case‐product level. Primary‐suspect records for semaglutide, tirzepatide, dulaglutide, liraglutide, exenatide, and lixisenatide were analysed using reporting odds ratios, proportional reporting ratios, and an approximate Information Component. Medicaid utilisation data, FDA labelling/Safety‐Related Labelling Changes resources, FDA shortage and compounded‐product communications, and Canada Vigilance reports provided contextual interpretation; no data source was used to estimate incidence, comparative risk, or causality.

Results

The final FAERS analysis set included 243 114 GLP‐1 primary‐suspect case‐product records within 8 995 547 background reports. Tirzepatide accounted for 133 100 records, followed by semaglutide (55619) and dulaglutide (38406). Frequently reported terms included incorrect dose administered, nausea, injection‐site pain, diarrhoea, vomiting, off‐label use, and extra dose administered. Prioritised domains included gastrointestinal intolerance, medication‐use/device events, impaired gastric emptying, pancreatobiliary events, renal/dehydration events, and hypoglycaemia. Canada Vigilance and FDA labelling/SrLC mapping showed descriptive visibility for most major domains, while medication‐use terms reflected use‐process rather than conventional adverse‐drug‐reaction issues.

Conclusions

Multi‐source pharmacovigilance can improve interpretation of GLP‐1 postmarketing safety evidence in diabetes and obesity care. Findings should be interpreted as signal‐prioritisation and medication‐safety evidence, not as incidence, proof of causality, or population‐level comparative risk, given the limited clinical interpretability of spontaneous‐reporting data.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacovigilanceObesityProduct Surveillance, PostmarketingHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2HumansTirzepatideSemaglutideUnited StatesGlucagon-Like PeptidesAdverse Drug Reaction Reporting SystemsExenatideLiraglutideUnited States Food and Drug AdministrationRecombinant Fusion ProteinsGlucagon-Like Peptide 1CanadaFemaleImmunoglobulin Fc Fragments

Stichwörter der Autor:innen

FAERSglucagon‐like peptide‐1medication errorpharmacovigilanceregulatory evidence mapping

Substanzen

TirzepatideSemaglutideHypoglycemic AgentsGlucagon-Like PeptidesExenatideGlucagon-Like Peptide-1 Receptor AgonistsLiraglutideRecombinant Fusion Proteinsdulaglutidelixisenatide

Autor:innen und Institutionen

  • Department of Pharmacy, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China.

ORCID-Profile: Yabin Ma

Förderung

  • Shanghai Municipal Science and Technology Commission Project
  • Pudong New District Health Technology Project

Zitieren

APA

Ren, L., Zhang, Y., Fang, F., & Ma, Y. (2026). Postmarketing Safety Signals and Medication‐Use Risks of GLP ‐1‐Based Therapies in Diabetes and Obesity: A Multi‐Source Pharmacovigilance and Regulatory Evidence‐Mapping Study. Diabetes, Obesity and Metabolism, 28(12), 11076-11085. https://doi.org/10.1111/dom.71303

Vancouver

Ren L, Zhang Y, Fang F, Ma Y. Postmarketing Safety Signals and Medication‐Use Risks of GLP ‐1‐Based Therapies in Diabetes and Obesity: A Multi‐Source Pharmacovigilance and Regulatory Evidence‐Mapping Study. Diabetes, Obesity and Metabolism. 2026;28(12):11076-11085. doi:10.1111/dom.71303

BibTeX
@article{Ren2026,
  author = {Ren, Long and Zhang, Yuan and Fang, Fang and Ma, Yabin},
  title = {Postmarketing Safety Signals and Medication‐Use Risks of GLP ‐1‐Based Therapies in Diabetes and Obesity: A Multi‐Source Pharmacovigilance and Regulatory Evidence‐Mapping Study},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {12},
  pages = {11076--11085},
  doi = {10.1111/dom.71303}
}
Kostenlos starten →